I need to check if there's enough substantive disclosure content. The filing includes financial statement references, share count (168,043,540 shares as of October 30, 2026), company description, and filing period details. While much of the text is boilerplate/cautionary language, there is substantive content exceeding 150 words including financial data references and company descriptions. However, looking carefully at what's actually disclosed in terms of financial figures: the filing text cuts off before the actual financial statements. What I have is: share count, filing period (Q3 ended September 30, 2026), company description as a "global biopharmaceutical company," mention of the Avadel Acquisition, mention of oncology business separation, and the product areas (alcohol dependence, opioid dependence, schizophrenia). Let me build the article from what's confirmed in the filing.

Alkermes Public Limited Company filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 3, 2026, disclosing 168,043,540 ordinary shares outstanding as of October 30, 2026.

Key Highlights

  • Share count: 168,043,540 ordinary shares, $0.01 par value, were outstanding as of October 30, 2026, according to the filing.
  • Quarterly period: The report covers the three and nine months ended September 30, 2026.
  • Large accelerated filer: The company indicated it is classified as a large accelerated filer under Exchange Act Rule 12b-2.
  • Avadel Acquisition referenced: The filing references the Avadel Acquisition, including expectations regarding anticipated benefits and synergies of the transaction.
  • Oncology separation noted: The filing references the completed separation of the company's oncology business and expectations regarding its tax treatment and other anticipated benefits.
  • Product focus: The company described itself as developing medicines in neuroscience, with commercial products for alcohol dependence, opioid dependence, and schizophrenia.

Alkermes Q3 2026 10-Q: Key Disclosures on Share Count, Acquisitions, and Business Scope

Alkermes Public Limited Company (NASDAQ:ALKS), incorporated in Ireland, filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the U.S. Securities and Exchange Commission. The filing covers both the three-month and nine-month periods ended September 30, 2026, and confirms that 168,043,540 ordinary shares with a par value of $0.01 were outstanding as of October 30, 2026.

According to the filing, the company is classified as a large accelerated filer and is not a shell company. The registrant disclosed that it has filed all required reports under the Securities Exchange Act of 1934 during the preceding 12 months and has submitted all required Interactive Data Files electronically. The company's principal executive offices are listed at Connaught House, 1 Burlington Road, Dublin 4, Ireland.

The filing references the Avadel Acquisition, noting expectations regarding "any anticipated benefits and synergies of the transaction," as well as the completed separation of the company's oncology business, including expectations regarding the "tax treatment and other anticipated benefits" of that separation. The company described itself as "a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience," with a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, and schizophrenia. The filing contains forward-looking statements that are subject to risks, assumptions, and uncertainties, as noted in the company's cautionary language.

What Was Disclosed

Alkermes filed its Form 10-Q for Q3 2026 covering the period ended September 30, 2026, disclosing 168,043,540 ordinary shares outstanding, its large accelerated filer status, references to the Avadel Acquisition, the completed oncology business separation, and its neuroscience-focused commercial product portfolio.